Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 additional multicenter study of intrathecal KP-100IT in acute spinal cord injury
jRCT2031260281Phase 3Recruiting
- Sponsor
- Kringle Pharma, Inc.
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of KP-100 in spinal cord injury (SCI), sponsored by Kringle Pharma, Inc. Primary endpoint: Primary efficacy endpoint. Started Jul 2026; status: recruiting.
02
Drugs
KP-100
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on jRCT2031260281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260281.